phase readout
saveNCT04744116: Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
RECRUITINGupdated 1mo ago
community read0 votes
Sponsor: M.D. Anderson Cancer Center. Phase: EARLY_PHASE1. Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease
view source ↗
comments(0)
5-min edit window · permanent after that